United Kingdom

Tova Cohen

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

21 Jun 2018

SkyHigh not the limit of McAfee's ambition, IPO an option

TEL AVIV Cybersecurity firm McAfee is looking at further acquisitions after buying security provider SkyHigh Networks this year and has not ruled out going public again to widen its options, its chief executive said.

21 Jun 2018

Israel's UroGen to start mid-stage bladder cancer trial

RAANANA, Israel Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced trial of a treatment for upper urinary tract cancer.

23 May 2018

Israel's defence expertise drives tech boom for autonomous cars

SHFAYIM, Israel Technology that has helped Israel's military drive tanks, guide and intercept missiles, and keep its computer systems secure is being redeployed in the development of driverless cars.

22 May 2018

Renault-Nissan-Mitsubishi VC invests first $50 million in startups

TEL AVIV The Renault-Nissan-Mitsubishi alliance's new venture capital fund has agreed five investments in four months totaling $50 million and will present another to its supervisory board next week, the fund's head said.

03 May 2018

Teva raises 2018 outlook, expects migraine drug approval by year-end

TEL AVIV Israel's heavily indebted Teva Pharmaceutical Industries raised its financial outlook for 2018 on Thursday after reporting a smaller than expected drop in first-quarter net profit and revenue.

02 May 2018

Migraine drug delay would compound Teva's troubles

TEL AVIV Teva Pharmaceutical Industries is counting on its new migraine treatment to haul it out of the doldrums. But a possible delay in U.S. approval and looming pricing battle are making the task harder.

01 May 2018

Permira to buy back Cisco's pay-TV software business

TEL AVIV Private equity firm Permira [PERM.UL] said on Tuesday it is buying back Cisco System's video software unit, six years after it sold the business to Cisco for $5 billion.

30 Apr 2018

FDA clears Pluristem radiation treatment for emergency use

HAIFA, Israel Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the U.S. Food and Drug Administration has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event.

25 Apr 2018

Check Point Software cuts 2018 revenue, profit forecast

TEL AVIV Network security provider Check Point Software Technologies cut its revenue and profit forecasts for 2018, despite just beating earnings estimates in the first quarter, saying it was taking longer to close deals for a new key product.

16 Apr 2018

Oracle co-CEO Catz expects acceleration in cloud business

TEL AVIV Oracle Corp co-CEO Safra Catz said on Monday she expected an acceleration in the company's cloud business after the software maker last month reported sales from this business that fell short of Wall Street forecasts.

  • Europe
  • U.S.
  • Asia
  • Sectors
Stock Search
FTSE 100 7,682.27 + 125.83 +1.67%
DAX 12,579.72 + 67.81 +0.54%
CAC 40 5,387.38 + 71.37 +1.34%
TR Europe 177.36 + 2.36 +1.35%
GBP/USD 1.3272 +0.03%
GBP/EUR 1.1383 +0.00%
EUR/USD 1.1655 +0.00%
Gold 1,270.20 +3.00 +0.24%
Oil 69.28 +3.74 +5.71%
Corn 357.00 +0.00 +0.00%